IL216211A - L45cdc peptides and vaccines containing them - Google Patents

L45cdc peptides and vaccines containing them

Info

Publication number
IL216211A
IL216211A IL216211A IL21621111A IL216211A IL 216211 A IL216211 A IL 216211A IL 216211 A IL216211 A IL 216211A IL 21621111 A IL21621111 A IL 21621111A IL 216211 A IL216211 A IL 216211A
Authority
IL
Israel
Prior art keywords
same
vaccines including
cdc45l peptides
cdc45l
peptides
Prior art date
Application number
IL216211A
Other languages
English (en)
Hebrew (he)
Other versions
IL216211A0 (en
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of IL216211A0 publication Critical patent/IL216211A0/en
Publication of IL216211A publication Critical patent/IL216211A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL216211A 2009-05-26 2011-11-08 L45cdc peptides and vaccines containing them IL216211A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21713309P 2009-05-26 2009-05-26
PCT/JP2010/003488 WO2010137295A1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Publications (2)

Publication Number Publication Date
IL216211A0 IL216211A0 (en) 2012-01-31
IL216211A true IL216211A (en) 2016-06-30

Family

ID=43222423

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216211A IL216211A (en) 2009-05-26 2011-11-08 L45cdc peptides and vaccines containing them

Country Status (16)

Country Link
US (1) US8586547B2 (enExample)
EP (4) EP3208334B1 (enExample)
JP (1) JP5903697B2 (enExample)
KR (1) KR101765452B1 (enExample)
CN (3) CN105153279B (enExample)
AU (1) AU2010253356B2 (enExample)
BR (1) BRPI1010666B1 (enExample)
CA (3) CA2762934C (enExample)
DK (3) DK3556857T3 (enExample)
ES (3) ES2631952T3 (enExample)
IL (1) IL216211A (enExample)
MX (1) MX2011012619A (enExample)
RU (1) RU2562160C2 (enExample)
SG (1) SG176058A1 (enExample)
TW (1) TWI507204B (enExample)
WO (1) WO2010137295A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771350B1 (en) 2011-10-28 2018-01-10 OncoTherapy Science, Inc. Topk peptides and vaccines including the same
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.
JP7281774B2 (ja) 2017-09-19 2023-05-26 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 抗ｈｌａ－ａ２抗体及びその使用方法
IL273401B2 (en) 2017-09-20 2025-05-01 Univ British Columbia Novel antibodies against human leukocyte antigens type A2 and their uses

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
US20020132252A1 (en) * 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
JP4413429B2 (ja) 1998-06-25 2010-02-10 株式会社グリーンペプタイド サイクロフィリンｂ由来の腫瘍抗原ペプチド
ES2747357T3 (es) 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
CN101139392B (zh) 2002-09-12 2012-12-26 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
JP4370409B2 (ja) 2005-06-22 2009-11-25 国立大学法人東北大学 がんの予後予測方法
EP2295571A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
ATE509096T1 (de) 2006-06-16 2011-05-15 Onco Therapy Science Inc Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
US8470534B2 (en) 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗

Also Published As

Publication number Publication date
ES2875950T3 (es) 2021-11-11
CA3011607A1 (en) 2010-12-02
CN102459589A (zh) 2012-05-16
TW201106962A (en) 2011-03-01
EP3556857A3 (en) 2019-12-04
CA2762934C (en) 2018-09-04
RU2011152975A (ru) 2013-07-10
ES2631952T3 (es) 2017-09-06
EP3868778A2 (en) 2021-08-25
DK3208334T3 (da) 2019-09-30
WO2010137295A1 (en) 2010-12-02
EP3208334A2 (en) 2017-08-23
CA2762934A1 (en) 2010-12-02
EP3556857B1 (en) 2021-05-05
SG176058A1 (en) 2011-12-29
MX2011012619A (es) 2012-01-30
ES2746334T3 (es) 2020-03-05
IL216211A0 (en) 2012-01-31
CN105153279A (zh) 2015-12-16
CA3011607C (en) 2022-09-13
EP3208334A3 (en) 2017-10-18
EP3868778A3 (en) 2021-11-03
US20120164163A1 (en) 2012-06-28
CN105153279B (zh) 2018-09-11
AU2010253356A1 (en) 2011-12-01
BRPI1010666B1 (pt) 2021-11-23
DK2435567T3 (en) 2017-07-24
TWI507204B (zh) 2015-11-11
CN103694315B (zh) 2015-07-29
EP2435567B1 (en) 2017-05-03
CN103694315A (zh) 2014-04-02
CN102459589B (zh) 2013-12-25
KR20120018203A (ko) 2012-02-29
KR101765452B1 (ko) 2017-08-07
RU2562160C2 (ru) 2015-09-10
EP2435567A1 (en) 2012-04-04
JP2012527867A (ja) 2012-11-12
EP3556857A2 (en) 2019-10-23
EP2435567A4 (en) 2013-03-13
US8586547B2 (en) 2013-11-19
EP3208334B1 (en) 2019-07-03
CA3167451A1 (en) 2010-12-02
DK3556857T3 (da) 2021-07-12
BRPI1010666A2 (pt) 2017-09-12
AU2010253356B2 (en) 2015-09-24
JP5903697B2 (ja) 2016-04-20

Similar Documents

Publication Publication Date Title
IL209967A0 (en) Cdca1 epitope peptides and vaccines containing the same
SG173751A1 (en) Foxm1 peptides and vaccines containing the same
IL229926A0 (en) 3neil peptides and vaccines containing them
IL228995A0 (en) b5sema peptides and components containing them
ZA201207416B (en) Cdca5 peptides and vaccines including the same
IL229956B (en) 1mphosph peptides and ingredients containing them
IL216211A0 (en) Cdc45l peptides and vaccines including the same
EP2430039A4 (en) TTK-PEPTIDES AND VACCINES CONTAINING THEM
ZA201303886B (en) Tomm34 peptides and vaccines including the same
IL214453A0 (en) Vangli peptides and vaccines including the same
IL213318A0 (en) C1orf59 peptides and vaccines including the same
IL220146A0 (en) Tmem22 peptides and vaccines including the same
IL221474A0 (en) Hjurp peptides and vaccines including the same
ZA201207342B (en) Ect2 peptides and vaccines including the same
IL215268A0 (en) C6orf167 peptides and vaccines containing the same
IL225553A0 (en) 54orf18c peptides and vaccines containing them
IL225552A0 (en) wdhd1 peptides and vaccines containing them
ZA201104890B (en) Wdrpuh epitope peptides and vaccines containing the same
IL215915A0 (en) Ttk peptides and vaccines including the same
HK1166096A (en) Vangl1 peptides and vaccines including the same
HK1170747A (en) Tmem22 peptides and vaccines including the same
HK1167663A (en) Ttk peptides and vaccines including the same
HK1183903A (en) C18orf54 peptides and vaccines including the same
HK1183902A (en) Wdhd1 peptides and vaccines including the same
HK1196397A (en) Sema5b peptides and vaccines including the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed